SAN ANTONIO, April 01, 2026--bioAffinity Technologies’ CyPath Lung Sales Surged 146% Year-Over-Year in Q1 2026, gaining ...

SAN ANTONIO, March 13, 2026--bioAffinity Technologies reports financial results for FY 2025, including record revenue and ...

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today ...

bioAffinity Technologies Inc BIAF shares are trading higher on Wednesday. The move follows an announcement regarding a new ...

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, ...

bioAffinity Technologies Inc BIAF shares are trading higher on Tuesday morning. The move follows the release of a new ...

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today ...

Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW) announced today that pursuant to warrant exercise agreements dated Aug. 2, 2024, three existing accredited investors ...

SAN ANTONIO, Texas--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251114274995/en/ The articles, information, and content displayed on this webpage ...

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today ...